I am preparing a poster for the above. This makes reference to this forum and I would like to ensure, therefore, that people are content with the words that I use.
My abstract has been accepted and is:
Continuing experimentation in the world of independent research raises questions about Rapamycin, the role of menaquinones in mitochondrial function, whether Parkinsons Disease and ALS/MND should be considered diseases of aging, what the role of transitions, transversions and deletions are in terms of the effects of mtDNA damage on gene expression and whether follicular atresia should be considered as part of the aging process.
I have put a draft of the poster on my citrate website. I intend first finalising the draft and then cutting it down to the format of an A0 poster. However, having a draft ensures that this forum can comment on any aspects that people think should be changed.
I am also intending to publish an infographic from the poster of which I published an earlier version here yesterday, but this is the current version with mistakes corrected.
You should update the text to mention that the highest dose (60uM) we’ve done resulted in an increase in the size of the worms similar to the size increase in rotifers. This, in combination with no evidence of toxicity at these doses, indicates that similar lifespan effects may be possible at higher doses, and this is why higher doses are being explored.
The link to the IPAM page on Rapamycin News you should change it to the original post, right now you’ve got it on a random comment on the post.
Additionally I am experimenting with IPAM myself. I have consumed it a few times but that isn’t really my focus as I won’t get much useful data from that. I can get some useful data from creating a topical formulation as I am seeing some interesting results in skin anti-aging effects which I want to explore further.
If we get the higher dose results before the event comes out please update the poster.
I am going to update the image to mention this study was done in worms and add a bit more information:
Because there are no word limits on the website I can easily add to that. I would not myself say “Doses were too low to change lifespan” as we don’t know they will change lifespan at a higher dose.
I will, of course, update the website when the results are out and if the results are in sufficient time to be printed in the poster (which is about 2 weeks before the conference) then I will have them in the poster.
What I will do is wait for any other comments on this topic and then do a single set of modifications to the web post.
Fair point. We will see what happens. But I think it’s still a true statement, if lifespan didn’t meaningfully go up or down then the dose is too low. Everything will have an effect at some dosage level.
Point mutations and the mutator mice
Vermulst et Al’s paper from 2006 which studied mutation quantification in the heterozygous and homozygous mutator mice warrants further comment. Although they did not study lifespan analysis this paper reported median lifespan estimates from previous papers (Trifunovic et al., 2004; Kujoth et al., 2005) where wildtype mice survived 864 days, homozygous mice survived 423 days and heterozygous mice survived 758 days. So there was an estimated 41% reduction in lifespan for homozygous and an estimated 12% reduction in lifespan for heterozygous. Although accurately reported in the paper that no statistically significant difference was detected (p=0.875) between heterozygous and wild type mice, the paper has been considered elsewhere as it concluded there was no difference rather than it did not find a difference. What was also found by Vermulst was that young heterozygous mice had a higher level of mutations than old wild type mice. From this it could be hypothesised that transitions (the main replication error) appear to have much less effect, perhaps an order of magnitude less, on the efficiency of the mitochondria than deletions and transversions (the main errors from ROS). They recognise in their paper that their methods would not detect large mtDNA deletions although they would detect small mtDNA deletions. Hence their paper does not conflict with the thesis that the mutations caused by the replication errors in DNA Polymerase Gamma cause a lifespan reduction in both the heterozygous and homozygous mutator mice compared to wild type, but this has a significantly less effect than mutations caused by ROS rather than replication errors. Importantly their paper does not conflict with the thesis that the main cause of aging is mitochondrial mutations caused by ROS rather than replication errors, but that replication errors do have a minor effect on aging.
Thanks for the support, John! Here is a text of the mTOR modulator project. If you need a shorter version just let me know.
Searching for a better Rapamycin
Rapamycin is the gold standard for lifespan extension, but better options may exist. Rapamycin Longevity Lab has already screened 300 mTOR-modulating compounds. Five of these outperformed Rapamycin’s 27% lifespan effect, with Omipalisib achieving a remarkable 63% increase.
Additional 300 compounds are soon to be screened once we obtain the remaining $23,400 funds needed. The goal with this project is to provide the field with important unique data to improve human longevity.
Donate: https://masteronething.com/mtor
I bought a month’s subscription for the mindthegraph infographic design system so I thought I might do some more before it runs out. I have finished the physical poster subject to changes from more results about IPAM, but I am updating the web page.
